How should I interpret spirometry results with FEV1/FVC 61%, FEV1 58% predicted, and FVC 71% predicted, and what treatment is indicated?

Moderate COPD with Airflow Obstruction

These spirometry results indicate moderate COPD (GOLD Grade 2) with airflow obstruction, and you should initiate long-acting bronchodilator therapy immediately.

Spirometry Interpretation

Your results show:

• FEV1/FVC ratio of 61% (0.61) - This is below the threshold of 0.70, confirming airflow obstruction 1, 2, 3
• FEV1 of 58% predicted - This places the patient in GOLD Grade 2 (moderate) severity
• FVC of 71% predicted - Mildly reduced but above the lower limit of normal (typically <80% in adults suggests restriction) 3

The pattern is obstructive because the FEV1/FVC ratio is reduced with a disproportionately lower FEV1 compared to FVC 1, 3.

Important Caveat on Age

If this patient is elderly (>60 years), be aware that using the fixed 0.70 threshold may lead to overdiagnosis in up to 35% of cases 4. However, with an FEV1/FVC of 0.61, this is well below even the more conservative threshold of 0.65 suggested for geriatric populations, so the obstruction diagnosis remains valid 4.

Treatment Recommendations

For moderate COPD with FEV1 58% predicted and bothersome respiratory symptoms (especially dyspnea), initiate long-acting inhaled bronchodilator therapy 5.

Specific Treatment Algorithm:

1. First-line therapy: Start with a long-acting bronchodilator (either long-acting β2-agonist [LABA] or long-acting muscarinic antagonist [LAMA])

   • These reduce exacerbations by 13-25% compared to placebo 5
   • Both classes have similar effectiveness 5

2. Consider combination therapy (LABA + inhaled corticosteroid) if:

   • Patient has repeated exacerbations
   • FEV1 drops below 50% predicted
   • Combination therapy showed mortality benefit compared to placebo (relative risk 0.82) and inhaled corticosteroids alone (relative risk 0.79), though absolute reductions were <1% 5

3. Add pulmonary rehabilitation: This improves health status and dyspnea in patients with FEV1 <60% predicted 5

4. Assess for bronchodilator reversibility: Perform post-bronchodilator testing to check if FEV1 improves by ≥12% AND ≥200 mL (≥0.2 L) in adults 3, 6

   • Significant reversibility suggests an asthma component
   • Even without meeting full reversibility criteria, smaller improvements may be clinically relevant 6

Critical Next Steps

• Obtain post-bronchodilator spirometry if not already done - this is essential for confirming COPD diagnosis and assessing reversibility 7
• Evaluate for hypoxemia: Check oxygen saturation; if resting hypoxia is present with symptoms, supplemental oxygen reduces mortality (relative risk 0.61) 5
• Assess symptom burden: Treatment decisions should be based on both spirometry AND symptoms, not spirometry alone 5

Common Pitfall to Avoid

Do not rely solely on pre-bronchodilator values for diagnosis or treatment decisions. Post-bronchodilator testing is the standard for confirming COPD 7. The current GOLD guidelines require post-bronchodilator FEV1/FVC <0.70 for definitive diagnosis.